Extended Data Table 3 AEs (≥20% in all cohorts) regardless of study drug relationship by maximum toxicity grade

From: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  1. Values are number of patients, n (%).
  2. Preferred terms by MedDRA version 23.0 and CTCAE version 4.0.
  3. All treated patients (primary and expansion cohorts).
  4. MedDRA, Medical Dictionary for Regulatory Activities.
Back to article page